Literature DB >> 2611088

Testing for bimodality in frequency distributions of data suggesting polymorphisms of drug metabolism--hypothesis testing.

P R Jackson1, G T Tucker, H F Woods.   

Abstract

1. The theory of methods of hypothesis testing in relation to the detection of bimodality in density distributions is discussed. 2. Practical problems arising from these methods are outlined. 3. The power of three methods of hypothesis testing was compared using simulated data from bimodal distributions with varying separation between components. None of the methods could determine bimodality until the separation between components was 2 standard deviation units and could only do so reliably (greater than 90%) when the separation was as great as 4-6 standard deviation units. 4. The robustness of a parametric and a non-parametric method of hypothesis testing was compared using simulated unimodal distributions known to deviate markedly from normality. Both methods had a high frequency of falsely indicating bimodality with distributions where the components had markedly differing variances. 5. A further test of robustness using power transformation of data from a normal distribution showed that the algorithms could accurately determine unimodality only when the skew of the distribution was in the range 0-1.45.

Mesh:

Substances:

Year:  1989        PMID: 2611088      PMCID: PMC1380036          DOI: 10.1111/j.1365-2125.1989.tb03558.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  9 in total

1.  Skewness in commingled distributions.

Authors:  C J Maclean; N E Morton; R C Elston; S Yee
Journal:  Biometrics       Date:  1976-09       Impact factor: 2.571

2.  Testing for bimodality in frequency distributions of data suggesting polymorphisms of drug metabolism--histograms and probit plots.

Authors:  P R Jackson; G T Tucker; H F Woods
Journal:  Br J Clin Pharmacol       Date:  1989-12       Impact factor: 4.335

3.  Statistical analysis of polymorphic drug metabolism data using the Rosin Rammler Sperling Weibull distribution.

Authors:  D B Jack
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

4.  Polymorphic hydroxylation of debrisoquine.

Authors:  G T Tucker; J H Silas; A O Iyun; M S Lennard; A J Smith
Journal:  Lancet       Date:  1977-10-01       Impact factor: 79.321

5.  Testing of single locus hypotheses where there is incomplete separation of the phenotypes.

Authors:  E A Murphy; D R Bolling
Journal:  Am J Hum Genet       Date:  1967-05       Impact factor: 11.025

6.  A simple method of resolution of a distribution into gaussian components.

Authors:  C G Bhattacharya
Journal:  Biometrics       Date:  1967-03       Impact factor: 2.571

7.  Metoprolol metabolism and debrisoquine oxidation polymorphism--population and family studies.

Authors:  J C McGourty; J H Silas; M S Lennard; G T Tucker; H F Woods
Journal:  Br J Clin Pharmacol       Date:  1985-12       Impact factor: 4.335

8.  The genetic control of sparteine and debrisoquine metabolism in man with new methods of analysing bimodal distributions.

Authors:  D A Evans; D Harmer; D Y Downham; E J Whibley; J R Idle; J Ritchie; R L Smith
Journal:  J Med Genet       Date:  1983-10       Impact factor: 6.318

9.  Polymorphic hydroxylation of Debrisoquine in man.

Authors:  A Mahgoub; J R Idle; L G Dring; R Lancaster; R L Smith
Journal:  Lancet       Date:  1977-09-17       Impact factor: 79.321

  9 in total
  10 in total

Review 1.  Inborn 'errors' of drug metabolism. Pharmacokinetic and clinical implications.

Authors:  M S Lennard; G T Tucker; H F Woods
Journal:  Clin Pharmacokinet       Date:  1990-10       Impact factor: 6.447

2.  A new, sensitive graphical method for detecting deviations from the normal distribution of drug responses: the NTV plot.

Authors:  L Endrenyi; M Patel
Journal:  Br J Clin Pharmacol       Date:  1991-08       Impact factor: 4.335

3.  Phenotypic debrisoquine 4-hydroxylase activity among extensive metabolizers is unrelated to genotype as determined by the Xba-I restriction fragment length polymorphism.

Authors:  J Turgeon; W E Evans; M V Relling; G R Wilkinson; D M Roden
Journal:  Br J Clin Pharmacol       Date:  1991-09       Impact factor: 4.335

4.  Evidence for the polymorphic oxidation of debrisoquine and proguanil in a Khmer (Cambodian) population.

Authors:  S Wanwimolruk; M R Thou; D J Woods
Journal:  Br J Clin Pharmacol       Date:  1995-08       Impact factor: 4.335

5.  Phenotypic polymorphism and gender-related differences of CYP1A2 activity in a Chinese population.

Authors:  D S Ou-Yang; S L Huang; W Wang; H G Xie; Z H Xu; Y Shu; H H Zhou
Journal:  Br J Clin Pharmacol       Date:  2000-02       Impact factor: 4.335

6.  Nonparametric expectation maximisation (NPEM) population pharmacokinetic analysis of caffeine disposition from sparse data in adult caucasians: systemic caffeine clearance as a biomarker for cytochrome P450 1A2 activity.

Authors:  Dimiter Terziivanov; Kristina Bozhinova; Velislava Dimitrova; Ivanka Atanasova
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

7.  Debrisoquine and mephenytoin oxidation in Sinhalese: a population study.

Authors:  K Weerasuriya; R L Jayakody; C A Smith; C R Wolf; G T Tucker; M S Lennard
Journal:  Br J Clin Pharmacol       Date:  1994-11       Impact factor: 4.335

8.  A novel and robust method for testing bimodality and characterizing porcine adipocytes of adipose tissue of 5 purebred lines of pig.

Authors:  Eric D Testroet; Peter Sherman; Chad Yoder; Amber Testroet; Carmen Reynolds; Mathew O'Neil; Soi Meng Lei; Donald C Beitz; Tom J Baas
Journal:  Adipocyte       Date:  2017-03-10       Impact factor: 4.534

9.  The roles of monkey M1 neuron classes in movement preparation and execution.

Authors:  Matthew T Kaufman; Mark M Churchland; Krishna V Shenoy
Journal:  J Neurophysiol       Date:  2013-05-22       Impact factor: 2.714

10.  N-Acetyltransferase-2 (NAT2) phenotype is influenced by genotype-environment interaction in Ethiopians.

Authors:  Eleni Aklillu; Juan Antonio Carrillo; Eyasu Makonnen; Leif Bertilsson; Natasa Djordjevic
Journal:  Eur J Clin Pharmacol       Date:  2018-03-27       Impact factor: 2.953

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.